RSAR: Post-marketing RX Drug Abuse Surveill Data Denver Health Data Source
Forecast overview
- Subagency
- FDA
- NAICS
- 541990
- Program office
- CDER ACQUISITION
Program continuity - Option Year 4 services. Allows FDA to conduct active surveillance of ADEs to inform regulatory actions and abuse prevention programs. Contract to obtain post-marketing prescription and over-the-counter drug abuse surveillance data generated from individuals entering or being assessed for substance abuse treatment. Fund Type Rationale: Funding to ensure program continuity. An increase in funding is proposed to increase the granularity of data for the receipt of additional stratified results. The fund type is split between PDUFA and GDUFA and involves all CDER medical products.
Related federal terms
- NAICS — North American Industry Classification System
Acquisition timeline
- Last verified on RFPCapture
- 2026-08-31
- Estimated solicitation
- 1/2026 (agency estimate)
- Estimated award
- 3/2026 (agency estimate)
- Expected period of performance end
- 3/2026 (agency estimate)
Market context
- NAICS market
- NAICS 541990
- Active contractors in this market
- 5 with relevant federal experience
Contractors with relevant federal experience
Action links
Track this forecast in CaptureIQ
Source
- Source
- HHS SBCX Forecast Export
- Source file
- Forecast.csv
- Official source
- Agency forecast source
- Last verified
- 2026-08-31